This multi-center randomized two-phase story through Ostfold Hospital Trust is looking to determine if maintenance therapy with low-dose rituximab is superior to placebo in prolonging responses among ITP patients who achieved an initial response with rituximab. The study also seeks to establish if the response to rituximab is greater in combination with dexamethasone, and what the true overall response rate and complete response rate is to rituximab. Health related quality of life will also be measured. This study is open to adults over the age of 18 years with newly diagnosed or persistent ITP only who have a platelet count less than 30K microliters.
Norway
https://clinicaltrials.gov/ct2/show/NCT03010202?recrs=a&cond=ITP&draw=1&rank=32
Recruiting
